Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome (II) + Temozolomide + Fluzoparib in Recurrent/Metastatic Ewing Sarcoma
NCT06827717Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection and fluzoparib in Ewing sarcoma, sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 4 months. Started Apr 2025; status: recruiting.
02
Drugs
irinotecan liposome injectionfluzoparib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT06827717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827717.